Lymphangitis medical therapy: Difference between revisions

Jump to navigation Jump to search
No edit summary
m (Bot: Removing from Primary care)
 
(74 intermediate revisions by 11 users not shown)
Line 1: Line 1:
__NOTOC__
__NOTOC__
{{Lymphangitis}}
{{Lymphangitis}}
 
{{CMG}}; {{AE}} {{VR}},{{Faizan}}{{VD}}
{{CMG}}; {{AE}} {{VR}}
 
==Overview==
==Overview==
Lymphangitis most often is an acute complication following an extension from the skin infection with the potential of a systemic spreadIt has to be promptly treated with appropriate [[antibiotics]] along with [[analgesics]], [[anti inflammatory medications]], warm and moist compresses. Certain conditions like nodular lymphagitis that is complicated by abscess and [[lymphedema]] with significant lymphatic obstruction may require surgical intervention.
Lymphangitis being a manifestation of wide concurrently occurring spectrum of manifestations or pathologies.The medical therapy varies from etiology to etiology. The mainstay of therapy for lymphangitis of infectious origin is antimicrobial therapySupportive therapy includes [[analgesics]], [[anti-inflammatory]] agents, and warm compresses. Specific anitmicrobial treatment for individual infections are discussed in detail separately.
 
==Medical Therapy==
==Principles of Therapy==
The mainstay of therapy for lymphangitis of infectious origin is antimicrobial therapy. Supportive therapy includes [[analgesics]], [[anti-inflammatory]] agents, and warm compresses.
*Prompt empirical antibiotic therapy that mostly covers [[beta-hemolytic streptococci]] should be started in order to prevent the rapid progression of lymphangitis.
*If the patients do not respond to the initial empirical antibiotic therapy or present with a systemic toxicity, then empiric coverage to [[methicillin-resistant staphylococcus aureus]] ([[MRSA]]) should be considered.
*Patients with mild to moderate disease can be managed in an outpatient setting and patients with severe disease should be managed in an inpatient setting.
*While treating the patients with antibiotics, the following should be considered
**[[Carbapenems]] should not be used in patients with a history of hypersensitivity to [[beta-lactam]]s.
**[[TMP-SMX]] is not recommended for women in the third trimester of pregnancy and in children under 2 months of age.        
**[[Tetracyclines]] should not be used in children under 8 years of age.
*Besides antibiotics, [[analgesics]], [[anti inflammatory medications]], hot and moist compresses can be used to control pain and inflammation.
*Chronic sporotrichoid form of lymphangitis can be treated with chemotherapy.
*Recurrent lymphangitis can lead to chronic [[lymphedema]], which can be treated with leg elevation, intermittent pneumatic compressions, manual massages, and multilayered bandage wrapping.


==Therapy Based on Clinical Form==
<ref name="lymphangitis">lymphanitis Mandell, GERALD L. "Mandell, Douglas, and Bennett's." Principles and practice of infectious diseases 7 (1995) Accessed on October 12,2016</ref>
===Acute Lymphangitis===
====Lymphangitis of infectious etiology====
====Empiric Therapy====
Common preferred and accepted therapy for lymphangitis of infectious origin include: Dicloxacillin or Cephalexin
<SMALL><font color="#FF4C4C">'''▸ Click on the following categories to expand treatment regimens.'''</font><ref name="pmid23466022">{{cite journal| author=Moran GJ, Abrahamian FM, Lovecchio F, Talan DA| title=Acute bacterial skin infections: developments since the 2005 Infectious Diseases Society of America (IDSA) guidelines. | journal=J Emerg Med | year= 2013 | volume= 44 | issue= 6 | pages= e397-412 | pmid=23466022 | doi=10.1016/j.jemermed.2012.11.050 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=23466022  }} </ref><ref name="pmid21208910">{{cite journal| author=Liu C, Bayer A, Cosgrove SE, Daum RS, Fridkin SK, Gorwitz RJ et al.| title=Clinical practice guidelines by the infectious diseases society of america for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children. | journal=Clin Infect Dis | year= 2011 | volume= 52 | issue= 3 | pages= e18-55 | pmid=21208910 | doi=10.1093/cid/ciq146 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=21208910  }} </ref></SMALL>
::* Preferred regimen: [[Dicloxacillin]]
::* Preferred regimen: [[Cephalexin]] 500 mg PO qid for 1 week
:*2. '''Patient with lymphangitis and if Community-Associated Methicillin-Resistant Staphylococcus Aureus (CA-MRSA) suspected''':
::* [[Trimethoprim-sulfamethoxazole]] PO bid  {{and}}  vancomycin 1 g IV every 12 hr
:* 3.'''Patient with lymphangitis allergic to penicillin''':
::* [[Clindamycin]] 300 mg PO qid for 7 days {{or}} [[Erythromycin]] 500 mg PO qid for 7 days {{or}} [[Levofloxacin]] 500 mg PO daily {{or}} [[Moxifloxacin]] 400 mg PO daily for 7 days.
====Empiric Therapy <small><small><small> ''Adapted from Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases.''<ref name="Mandell">{{Cite book  | last1 = Mandell | first1 = Gerald L. | last2 = Bennett | first2 = John E. (John Eugene) | last3 = Dolin | first3 = Raphael. | title = Mandell, Douglas, and Bennett's principles and practice of infectious disease | date = 2010 | publisher = Churchill Livingstone/Elsevier | location = Philadelphia, PA | isbn = | pages = }}</ref>''Adapted from Clin Infect Dis. 2005 Nov 15;41(10):1373-406.''<ref name="pmid16231249">{{cite journal| author=Stevens DL, Bisno AL, Chambers HF, Everett ED, Dellinger P, Goldstein EJ et al.| title=Practice guidelines for the diagnosis and management of skin and soft-tissue infections. | journal=Clin Infect Dis | year= 2005 | volume= 41 | issue= 10 | pages= 1373-406 | pmid=16231249 | doi=10.1086/497143 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=16231249  }} </ref> ''J Emerg Med. 2013 Jun;44(6):e397-412.''<ref name="pmid23466022">{{cite journal| author=Moran GJ, Abrahamian FM, Lovecchio F, Talan DA| title=Acute bacterial skin infections: developments since the 2005 Infectious Diseases Society of America (IDSA) guidelines. | journal=J Emerg Med | year= 2013 | volume= 44 | issue= 6 | pages= e397-412 | pmid=23466022 | doi=10.1016/j.jemermed.2012.11.050 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=23466022  }} </ref>''Clin Infect Dis. 2011 Feb 1;52(3):e18-55.''<ref name="pmid21208910">{{cite journal| author=Liu C, Bayer A, Cosgrove SE, Daum RS, Fridkin SK, Gorwitz RJ et al.| title=Clinical practice guidelines by the infectious diseases society of america for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children. | journal=Clin Infect Dis | year= 2011 | volume= 52 | issue= 3 | pages= e18-55 | pmid=21208910 | doi=10.1093/cid/ciq146 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=21208910  }} </ref></small></small></small>====
<SMALL><font color="#FF4C4C">'''▸ Click on the following categories to expand treatment regimens.'''</font></SMALL>


{|
{|
| valign=top |
| valign=top |
<div style="border-radius: 5px 5px 0 0; border: solid 1px #20538D; border-bottom: 0px; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5); box-shadow: inset 0 1px 1px rgba(255, 255, 255, 0.5), 0 1px 1px rgba(0, 0, 0, 0.5); height: 30px; line-height: 30px; width: 310px; background: #A1BCDD; text-align: center;">
<div style="border-radius: 5px 5px 0 0; border: solid 1px #20538D; border-bottom: 0px; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5); box-shadow: inset 0 1px 1px rgba(255, 255, 255, 0.5), 0 1px 1px rgba(0, 0, 0, 0.5); height: 30px; line-height: 30px; width: 320px; background: #A1BCDD; text-align: center;">
<font color="#FFF">
<font color="#FFF">
'''Mild - Moderate Acute Lymphangitis'''
'''Mild - Moderate Acute Lymphangitis'''
Line 32: Line 27:
</div>
</div>


<div class="mw-customtoggle-table01" style="cursor: pointer; border-radius: 0 0 0 0; border: solid 1px #20538D; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5); box-shadow: inset 0 1px 1px rgba(255, 255, 255, 0.5), 0 1px 1px rgba(0, 0, 0, 0.5); height: 30px; line-height: 30px; width: 310px; background: #4479BA;">
<div class="mw-customtoggle-table01" style="cursor: pointer; border-radius: 0 0 0 0; border: solid 1px #20538D; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5); box-shadow: inset 0 1px 1px rgba(255, 255, 255, 0.5), 0 1px 1px rgba(0, 0, 0, 0.5); height: 30px; line-height: 30px; width: 320px; background: #4479BA;">
<font color="#FFF">
<font color="#FFF">
&nbsp;&nbsp;▸&nbsp;&nbsp;'''Adults'''
&nbsp;&nbsp;▸&nbsp;&nbsp;'''Adults'''
Line 38: Line 33:
</div>
</div>


<div class="mw-customtoggle-table02" style="cursor: pointer; border-radius: 0 0 0 0; border: solid 1px #20538D; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5); box-shadow: inset 0 1px 1px rgba(255, 255, 255, 0.5), 0 1px 1px rgba(0, 0, 0, 0.5); height: 30px; line-height: 30px; width: 310px; background: #4479BA;">
<div class="mw-customtoggle-table02" style="cursor: pointer; border-radius: 0 0 0 0; border: solid 1px #20538D; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5); box-shadow: inset 0 1px 1px rgba(255, 255, 255, 0.5), 0 1px 1px rgba(0, 0, 0, 0.5); height: 30px; line-height: 30px; width: 320px; background: #4479BA;">
<font color="#FFF">
<font color="#FFF">
&nbsp;&nbsp;▸&nbsp;&nbsp;'''Children age >28 days'''
&nbsp;&nbsp;▸&nbsp;&nbsp;'''Children age >28 days'''
Line 44: Line 39:
</div>
</div>


<div style="border-radius: 5px 5px 0 0; border: solid 1px #20538D; border-bottom: 0px; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5); box-shadow: inset 0 1px 1px rgba(255, 255, 255, 0.5), 0 1px 1px rgba(0, 0, 0, 0.5); height: 30px; line-height: 30px; width: 310px; background: #A1BCDD; text-align: center;">
<div style="border-radius: 0 0 0 0; border: solid 1px #20538D; border-bottom: 0px; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5); box-shadow: inset 0 1px 1px rgba(255, 255, 255, 0.5), 0 1px 1px rgba(0, 0, 0, 0.5); height: 30px; line-height: 30px; width: 320px; background: #A1BCDD; text-align: center;">
<font color="#FFF">
<font color="#FFF">
'''Severe Acute Lymphangitis'''
'''Severe Acute Lymphangitis'''
Line 50: Line 45:
</div>
</div>


<div class="mw-customtoggle-table03" style="cursor: pointer; border-radius: 0 0 0 0; border: solid 1px #20538D; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5); box-shadow: inset 0 1px 1px rgba(255, 255, 255, 0.5), 0 1px 1px rgba(0, 0, 0, 0.5); height: 30px; line-height: 30px; width: 310px; background: #4479BA;">
<div class="mw-customtoggle-table03" style="cursor: pointer; border-radius: 0 0 0 0; border: solid 1px #20538D; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5); box-shadow: inset 0 1px 1px rgba(255, 255, 255, 0.5), 0 1px 1px rgba(0, 0, 0, 0.5); height: 30px; line-height: 30px; width: 320px; background: #4479BA;">
<font color="#FFF">
<font color="#FFF">
&nbsp;&nbsp;▸&nbsp;&nbsp;'''Adults'''
&nbsp;&nbsp;▸&nbsp;&nbsp;'''Adults'''
Line 56: Line 51:
</div>
</div>


<div class="mw-customtoggle-table04" style="cursor: pointer; border-radius: 0 0 5px 5px; border: solid 1px #20538D; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5); box-shadow: inset 0 1px 1px rgba(255, 255, 255, 0.5), 0 1px 1px rgba(0, 0, 0, 0.5); height: 30px; line-height: 30px; width: 310px; background: #4479BA;">
<div class="mw-customtoggle-table04" style="cursor: pointer; border-radius: 0 0 5px 5px; border: solid 1px #20538D; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5); box-shadow: inset 0 1px 1px rgba(255, 255, 255, 0.5), 0 1px 1px rgba(0, 0, 0, 0.5); height: 30px; line-height: 30px; width: 320px; background: #4479BA;">
<font color="#FFF">
<font color="#FFF">
&nbsp;&nbsp;▸&nbsp;&nbsp;'''Children age >28 days'''
&nbsp;&nbsp;▸&nbsp;&nbsp;'''Children age >28 days'''
Line 79: Line 74:
| style="padding: 0 5px; font-size: 90%; background: #F5F5F5;" align=center | '''''For Suspected Methicillin-Resistant Staphylococcus Aureus (MRSA)'''''
| style="padding: 0 5px; font-size: 90%; background: #F5F5F5;" align=center | '''''For Suspected Methicillin-Resistant Staphylococcus Aureus (MRSA)'''''
|-
|-
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | ▸ '''''[[Clindamycin]] 300-450 mg PO q8h'''''<BR> OR <BR>▸ '''''[[TMP-SMX]] 1 or 2 double-strength tablets ((sulfamethoxazole 800 mg; trimethoprim 160 mg) PO q12h'''''<BR> OR <BR>▸ '''''[[Doxycycline]] 100 mg PO q12h'''''<BR> OR <BR> ▸ '''''[[Minocycline]] 100 mg PO q12h'''''<BR> OR <BR> ▸ '''''[[Linezolid]] 600 mg PO q12h'''''
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | ▸ '''''[[Clindamycin]] 300-450 mg PO q8h'''''<BR> OR <BR>▸ '''''[[TMP-SMX]] 1 or 2 double-strength tablets (160/800 mg) PO q12h'''''<BR> OR <BR>▸ '''''[[Doxycycline]] 100 mg PO q12h'''''<BR> OR <BR> ▸ '''''[[Minocycline]] 100 mg PO q12h'''''<BR> OR <BR> ▸ '''''[[Linezolid]] 600 mg PO q12h'''''
|-
|-
| style="padding: 0 5px; font-size: 90%; background: #F5F5F5;" align=center | '''''For Suspected Beta-Hemolytic Streptococci and Methicillin-Resistant Staphylococcus Aureus (MRSA)'''''
| style="padding: 0 5px; font-size: 90%; background: #F5F5F5;" align=center | '''''For Suspected Beta-Hemolytic Streptococci and Methicillin-Resistant Staphylococcus Aureus (MRSA)'''''
|-
|-
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | ▸ '''''[[Clindamycin]] 300-450 mg PO q8h'''''<BR> OR <BR>▸ '''''[[Amoxicillin]] 500 mg PO q8h PLUS [[TMP-SMX]] 1 or 2 double-strength tablets ((sulfamethoxazole 800 mg; trimethoprim 160 mg) PO q12h'''''<BR> OR <BR>▸ '''''[[Amoxicillin]] 500 mg PO q8h PLUS [[Doxycycline]] 100 mg PO q12h'''''<BR> OR <BR> ▸ '''''[[Amoxicillin]] 500 mg PO q8h PLUS [[Minocycline]] 100 mg PO q12h'''''<BR> OR <BR> ▸ '''''[[Linezolid]] 600 mg PO q12h'''''
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | ▸ '''''[[Clindamycin]] 300-450 mg PO q8h'''''
|-
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | OR
|-
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | ▸ '''''[[Amoxicillin]] 500 mg PO q8h'''''<BR> PLUS <BR> ▸ '''''[[TMP-SMX]] 1 or 2 double-strength tablets (sulfamethoxazole 800 mg; trimethoprim 160 mg) PO q12h'''''<BR> OR <BR> ▸ '''''[[Doxycycline]] 100 mg PO q12h'''''<BR> OR <BR> ▸ '''''[[Minocycline]] 100 mg PO q12h'''''
|-
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | OR  
|-
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left |▸ '''''[[Linezolid]] 600 mg PO q12h'''''
|-
|-
| style="padding: 0 5px; font-size: 90%; background: #F5F5F5;" align=center | '''''For Animal Bites'''''
| style="padding: 0 5px; font-size: 90%; background: #F5F5F5;" align=center | '''''For Animal Bites'''''
Line 91: Line 94:
|}
|}
|}
|}
{| class="mw-collapsible mw-collapsed" id="mw-customcollapsible-table02" style="background: #FFFFFF;"
{| class="mw-collapsible mw-collapsed" id="mw-customcollapsible-table02" style="background: #FFFFFF;"
| valign=top |
| valign=top |
Line 99: Line 101:
| style="padding: 0 5px; font-size: 90%; background: #F5F5F5;" align=center | '''''Preferred Regimen'''''
| style="padding: 0 5px; font-size: 90%; background: #F5F5F5;" align=center | '''''Preferred Regimen'''''
|-
|-
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | ▸ '''''[[Penicillin V]] 500 mg PO q6h'''''
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | ▸ '''''[[Penicillin V]] < 12 years-old 25-50 mg/kg/day PO divided q6-8h (maximum 3 g/day), > 12 years-old 250-500 mg PO q6-8h'''''
|-
|-
| style="padding: 0 5px; font-size: 90%; background: #F5F5F5;" align=center | '''''Alternative Regimen'''''
| style="padding: 0 5px; font-size: 90%; background: #F5F5F5;" align=center | '''''Alternative Regimen'''''
Line 109: Line 111:
| style="padding: 0 5px; font-size: 90%; background: #F5F5F5;" align=center | '''''For Suspected Methicillin-Resistant Staphylococcus Aureus (MRSA)'''''
| style="padding: 0 5px; font-size: 90%; background: #F5F5F5;" align=center | '''''For Suspected Methicillin-Resistant Staphylococcus Aureus (MRSA)'''''
|-
|-
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | ▸ '''''[[Clindamycin]] 10-13 mg/kg PO q6-8h'''''<BR> OR <BR> ▸ '''''[[TMP-SMX]] 8–12 mg/kg (based on trimethoprim component) PO q12h'''''<BR> OR <BR> ▸ '''''[[Doxycycline]] ≤45 kg: 2 mg/kg PO q12h; >45 kg: 100 mg PO q12h'''''<BR> OR <BR> ▸ '''''[[Minocycline]] 2 mg/kg PO q12h'''''<BR> OR <BR> ▸ '''''[[Linezolid]] 10 mg/kg PO q8h'''''
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | ▸ '''''[[Clindamycin]] 10-13 mg/kg PO q6-8h'''''<BR> OR <BR> ▸ '''''[[TMP-SMX]] 8–12 mg/kg (based on trimethoprim component) PO q12h'''''<BR> OR <BR> ▸ '''''[[Doxycycline]]≤45 kg: 2 mg/kg PO q12h; >45 kg: 100 mg PO q12h'''''<BR> OR <BR> ▸ '''''[[Minocycline]] 2 mg/kg PO q12h '''''<BR> OR <BR> ▸ '''''[[Linezolid]] 10 mg/kg PO q8h'''''
|-
| style="padding: 0 5px; font-size: 90%; background: #F5F5F5" align=left | <SMALL><sup>¶</sup> Not recommended for children < 8 years of age </small>
|-
|-
| style="padding: 0 5px; font-size: 90%; background: #F5F5F5;" align=center | '''''For Suspected Beta-Hemolytic Streptococci and Methicillin-Resistant Staphylococcus Aureus (MRSA)'''''
| style="padding: 0 5px; font-size: 90%; background: #F5F5F5;" align=center | '''''For Suspected Beta-Hemolytic Streptococci and Methicillin-Resistant Staphylococcus Aureus (MRSA)'''''
|-
|-
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | '''''[[Clindamycin]] 10-13 mg/kg PO q6-8h'''''<BR> OR <BR>▸ '''''[[Amoxicillin]] 25-50 mg/kg PO q8h PLUS [[TMP-SMX]] 8–12 mg/kg (based on trimethoprim component) PO q12h'''''<BR> OR <BR>▸ '''''[[Amoxicillin]] 25-50 mg/kg PO q8h PLUS [[Doxycycline]] ≤45 kg: 2 mg/kg PO q12h; >45 kg: 100 mg PO q12h'''''<BR> OR <BR> ▸ '''''[[Amoxicillin]] 25-50 mg/kg PO q8h PLUS [[Minocycline]] 2 mg/kg PO q12h'''''<BR> OR <BR> ▸ '''''[[Linezolid]] 10 mg/kg PO q8h'''''
|-
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left |'''''[[Clindamycin]] 10-13 mg/kg IV q6-8h'''''
|-
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | OR
|-
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | ▸ '''''[[Amoxicillin]] 500 mg PO q8h'''''<BR> PLUS <BR> ▸ '''''[[TMP-SMX]] 8–12 mg/kg (based on trimethoprim component) PO q12h'''''<BR> OR <BR> ▸ '''''[[Doxycycline]]≤45 kg: 2 mg/kg PO q12h; >45 kg: 100 mg PO q12h'''''<BR> OR <BR> ▸ '''''[[Minocycline]]2 mg/kg PO q12h'''''
|-
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | OR  
|-
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left |▸ '''''[[Linezolid]] 10 mg/kg PO q8h'''''
|-
|-
| style="padding: 0 5px; font-size: 90%; background: #F5F5F5" align=left | <SMALL><sup>¶</sup> Not recommended for children < 8 years of age </small>
|-
|-
|-
| style="padding: 0 5px; font-size: 90%; background: #F5F5F5;" align=center | '''''For Animal Bites'''''
| style="padding: 0 5px; font-size: 90%; background: #F5F5F5;" align=center | '''''For Animal Bites'''''
Line 135: Line 152:
| style="padding: 0 5px; font-size: 90%; background: #F5F5F5;" align=center | '''''For Suspected Methicillin-Sensitive Staphylococcus Aureus (MSSA)'''''
| style="padding: 0 5px; font-size: 90%; background: #F5F5F5;" align=center | '''''For Suspected Methicillin-Sensitive Staphylococcus Aureus (MSSA)'''''
|-
|-
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | ▸ '''''[[Nafcillin]] 1-2 g IV q4h'''''<BR> OR <BR> ▸ '''''[[Oxacillin]] 1-2 g IV q4h'''''<BR> OR <BR> ▸ '''''[[Cefazolin]] 1 g IV q8h'''''<BR> OR <BR> ▸ '''''[[Clindamycin]] 300-450 mg PO q8h'''''<BR> OR <BR> ▸ '''''[[Erythromycin]] 500 mg PO q6h'''''
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | ▸ '''''[[Nafcillin]] 1-2 g IV q4h'''''<BR> OR <BR> ▸ '''''[[Oxacillin]] 1-2 g IV q4h'''''<BR> OR <BR> ▸ '''''[[Cefazolin]] 1 g IV q8h'''''<BR> OR <BR> ▸ '''''[[Clindamycin]] 300-450 mg PO q8h'''''
|-
|-
| style="padding: 0 5px; font-size: 90%; background: #F5F5F5;" align=center | '''''For Suspected Methicillin-Resistant Staphylococcus Aureus (MRSA)'''''
| style="padding: 0 5px; font-size: 90%; background: #F5F5F5;" align=center | '''''For Suspected Methicillin-Resistant Staphylococcus Aureus (MRSA)'''''
|-
|-
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | ▸ '''''[[Vancomycin]] 15-20 mg/kg IV q8-12h'''''<BR> OR <BR> ▸ '''''[[Linezolid]] 600 mg IV q12h'''''<BR> OR <BR> ▸ '''''[[Daptomycin]] 4mg/kg IV q24h '''''<BR> OR <BR> ▸ '''''[[Clindamycin]] 600 mg IV/PO q8h'''''<BR> OR <BR> ▸ '''''[[Telavancin]] 10 mg/kg IV q12h'''''
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | ▸ '''''[[Vancomycin]] 15-20 mg/kg IV q8-12h'''''<BR> OR <BR> ▸ '''''[[Linezolid]] 600 mg IV/PO q12h'''''<BR> OR <BR> ▸ '''''[[Daptomycin]] 4mg/kg IV q24h '''''<BR> OR <BR> ▸ '''''[[Clindamycin]] 600 mg IV/PO q8h'''''<BR> OR <BR> ▸ '''''[[Telavancin]] 10 mg/kg IV q12h'''''
|-
|-
| style="padding: 0 5px; font-size: 90%; background: #F5F5F5;" align=center | '''''For Suspected Beta-Hemolytic Streptococci and Methicillin-Resistant Staphylococcus Aureus (MRSA)'''''
| style="padding: 0 5px; font-size: 90%; background: #F5F5F5;" align=center | '''''For Suspected Beta-Hemolytic Streptococci and Methicillin-Resistant Staphylococcus Aureus (MRSA)'''''
|-  
|-  
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | ▸ '''''[[Clindamycin]] 300-450 mg PO q8h'''''<BR> OR <BR>▸ '''''[[Amoxicillin]] 500 mg PO q8h PLUS [[TMP-SMX]] 1 or 2 double-strength tablets ((sulfamethoxazole 800 mg; trimethoprim 160 mg) PO q12h'''''<BR> OR <BR>▸ '''''[[Amoxicillin]] 500 mg PO q8h PLUS [[Doxycycline]] 100 mg PO q12h'''''<BR> OR <BR> ▸ '''''[[Amoxicillin]] 500 mg PO q8h PLUS [[Minocycline]] 100 mg PO q12h'''''<BR> OR <BR> ▸ '''''[[Linezolid]] 600 mg PO q12h'''''  
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | ▸ '''''[[Clindamycin]] 600 mg IV/PO q8h'''''<BR> OR <BR> ▸ '''''[[Linezolid]] 600 mg IV/PO q12h'''''  
|-
|-
| style="padding: 0 5px; font-size: 90%; background: #F5F5F5;" align=center | '''''For Animal Bites'''''
| style="padding: 0 5px; font-size: 90%; background: #F5F5F5;" align=center | '''''For Animal Bites'''''
Line 173: Line 190:
| style="padding: 0 5px; font-size: 90%; background: #F5F5F5;" align=center | '''''For Suspected Beta-Hemolytic Streptococci and Methicillin-Resistant Staphylococcus Aureus (MRSA)'''''
| style="padding: 0 5px; font-size: 90%; background: #F5F5F5;" align=center | '''''For Suspected Beta-Hemolytic Streptococci and Methicillin-Resistant Staphylococcus Aureus (MRSA)'''''
|-
|-
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | '''''[[Clindamycin]] 10-13 mg/kg PO q6-8h'''''<BR> OR <BR>▸ '''''[[Amoxicillin]] 25-50 mg/kg PO q8h PLUS [[TMP-SMX]] 8–12 mg/kg (based on trimethoprim component) PO q12h'''''<BR> OR <BR>▸ '''''[[Amoxicillin]] 25-50 mg/kg PO q8h PLUS [[Doxycycline]] ≤45 kg: 2 mg/kg PO q12h; >45 kg: 100 mg PO q12h'''''<BR> OR <BR> ▸ '''''[[Amoxicillin]] 25-50 mg/kg PO q8h PLUS [[Minocycline]] 2 mg/kg PO q12h'''''<BR> OR <BR> ▸ '''''[[Linezolid]] 10 mg/kg PO q8h'''''
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left |'''''[[Clindamycin]] 10-13 mg/kg IV/PO q6-8h''''' <BR> OR <BR> ▸'''''[[Linezolid]] 10 mg/kg IV/PO q8h'''''
|-
|-
| style="padding: 0 5px; font-size: 90%; background: #F5F5F5;" align=center | '''''For Animal Bites'''''
| style="padding: 0 5px; font-size: 90%; background: #F5F5F5;" align=center | '''''For Animal Bites'''''
Line 183: Line 200:
|}
|}


====Pathogen Based Therapy====
====Pathogen Based Therapy <small><small><small> ''Adapted from Clin Infect Dis. 2005 Nov 15;41(10):1373-406.''<ref name="pmid16231249">{{cite journal| author=Stevens DL, Bisno AL, Chambers HF, Everett ED, Dellinger P, Goldstein EJ et al.| title=Practice guidelines for the diagnosis and management of skin and soft-tissue infections. | journal=Clin Infect Dis | year= 2005 | volume= 41 | issue= 10 | pages= 1373-406 | pmid=16231249 | doi=10.1086/497143 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=16231249  }} </ref> ''J Emerg Med. 2013 Jun;44(6):e397-412.''<ref name="pmid23466022">{{cite journal| author=Moran GJ, Abrahamian FM, Lovecchio F, Talan DA| title=Acute bacterial skin infections: developments since the 2005 Infectious Diseases Society of America (IDSA) guidelines. | journal=J Emerg Med | year= 2013 | volume= 44 | issue= 6 | pages= e397-412 | pmid=23466022 | doi=10.1016/j.jemermed.2012.11.050 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=23466022  }} </ref>''Clin Infect Dis. 2011 Feb 1;52(3):e18-55.''<ref name="pmid21208910">{{cite journal| author=Liu C, Bayer A, Cosgrove SE, Daum RS, Fridkin SK, Gorwitz RJ et al.| title=Clinical practice guidelines by the infectious diseases society of america for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children. | journal=Clin Infect Dis | year= 2011 | volume= 52 | issue= 3 | pages= e18-55 | pmid=21208910 | doi=10.1093/cid/ciq146 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=21208910  }} </ref></small></small></small>====


<SMALL><font color="#FF4C4C">'''▸ Click on the following categories to expand treatment regimens.'''</font><ref name="pmid23466022">{{cite journal| author=Moran GJ, Abrahamian FM, Lovecchio F, Talan DA| title=Acute bacterial skin infections: developments since the 2005 Infectious Diseases Society of America (IDSA) guidelines. | journal=J Emerg Med | year= 2013 | volume= 44 | issue= 6 | pages= e397-412 | pmid=23466022 | doi=10.1016/j.jemermed.2012.11.050 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=23466022  }} </ref><ref name="pmid21208910">{{cite journal| author=Liu C, Bayer A, Cosgrove SE, Daum RS, Fridkin SK, Gorwitz RJ et al.| title=Clinical practice guidelines by the infectious diseases society of america for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children. | journal=Clin Infect Dis | year= 2011 | volume= 52 | issue= 3 | pages= e18-55 | pmid=21208910 | doi=10.1093/cid/ciq146 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=21208910  }} </ref></SMALL>
<SMALL><font color="#FF4C4C">'''▸ Click on the following categories to expand treatment regimens.'''</font></SMALL>


{|
{|
| valign=top |
| valign=top |
<div style="border-radius: 5px 5px 0 0; border: solid 1px #20538D; border-bottom: 0px; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5); box-shadow: inset 0 1px 1px rgba(255, 255, 255, 0.5), 0 1px 1px rgba(0, 0, 0, 0.5); height: 30px; line-height: 30px; width: 310px; background: #A1BCDD; text-align: center;">
<div style="border-radius: 5px 5px 0 0; border: solid 1px #20538D; border-bottom: 0px; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5); box-shadow: inset 0 1px 1px rgba(255, 255, 255, 0.5), 0 1px 1px rgba(0, 0, 0, 0.5); height: 30px; line-height: 30px; width: 320px; background: #A1BCDD; text-align: center;">
<font color="#FFF">
<font color="#FFF">
'''Bacteria'''
'''Bacteria'''
Line 195: Line 212:
</div>
</div>


<div class="mw-customtoggle-table05" style="cursor: pointer; border-radius: 0 0 0 0; border: solid 1px #20538D; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5); box-shadow: inset 0 1px 1px rgba(255, 255, 255, 0.5), 0 1px 1px rgba(0, 0, 0, 0.5); height: 30px; line-height: 30px; width: 310px; background: #4479BA;">
<div class="mw-customtoggle-table05" style="cursor: pointer; border-radius: 0 0 0 0; border: solid 1px #20538D; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5); box-shadow: inset 0 1px 1px rgba(255, 255, 255, 0.5), 0 1px 1px rgba(0, 0, 0, 0.5); height: 30px; line-height: 30px; width: 320px; background: #4479BA;">
<font color="#FFF">
<font color="#FFF">
&nbsp;&nbsp;▸&nbsp;&nbsp;'''Streptococcus Pyogenes'''
&nbsp;&nbsp;▸&nbsp;&nbsp;'''Streptococcus Pyogenes'''
Line 201: Line 218:
</div>
</div>


<div class="mw-customtoggle-table06" style="cursor: pointer; border-radius: 0 0 0 0; border: solid 1px #20538D; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5); box-shadow: inset 0 1px 1px rgba(255, 255, 255, 0.5), 0 1px 1px rgba(0, 0, 0, 0.5); height: 30px; line-height: 30px; width: 310px; background: #4479BA;">
<div class="mw-customtoggle-table06" style="cursor: pointer; border-radius: 0 0 0 0; border: solid 1px #20538D; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5); box-shadow: inset 0 1px 1px rgba(255, 255, 255, 0.5), 0 1px 1px rgba(0, 0, 0, 0.5); height: 30px; line-height: 30px; width: 320px; background: #4479BA;">
<font color="#FFF">
<font color="#FFF">
&nbsp;&nbsp;▸&nbsp;&nbsp;'''Methicillin Sensitive Staphylococcus Aureus'''
&nbsp;&nbsp;▸&nbsp;&nbsp;'''Methicillin Sensitive Staphylococcus Aureus'''
Line 207: Line 224:
</div>
</div>


<div class="mw-customtoggle-table07" style="cursor: pointer; border-radius: 0 0 0 0; border: solid 1px #20538D; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5); box-shadow: inset 0 1px 1px rgba(255, 255, 255, 0.5), 0 1px 1px rgba(0, 0, 0, 0.5); height: 30px; line-height: 30px; width: 310px; background: #4479BA;">
<div class="mw-customtoggle-table07" style="cursor: pointer; border-radius: 0 0 0 0; border: solid 1px #20538D; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5); box-shadow: inset 0 1px 1px rgba(255, 255, 255, 0.5), 0 1px 1px rgba(0, 0, 0, 0.5); height: 30px; line-height: 30px; width: 320px; background: #4479BA;">
<font color="#FFF">
<font color="#FFF">
&nbsp;&nbsp;▸&nbsp;&nbsp;'''Methicillin Resistant Staphylococcus Aureus'''
&nbsp;&nbsp;▸&nbsp;&nbsp;'''Methicillin Resistant Staphylococcus Aureus'''
Line 213: Line 230:
</div>
</div>


<div class="mw-customtoggle-table08" style="cursor: pointer; border-radius: 0 0 5px 5px; border: solid 1px #20538D; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5); box-shadow: inset 0 1px 1px rgba(255, 255, 255, 0.5), 0 1px 1px rgba(0, 0, 0, 0.5); height: 30px; line-height: 30px; width: 310px; background: #4479BA;">
<div class="mw-customtoggle-table08" style="cursor: pointer; border-radius: 0 0 5px 5px; border: solid 1px #20538D; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5); box-shadow: inset 0 1px 1px rgba(255, 255, 255, 0.5), 0 1px 1px rgba(0, 0, 0, 0.5); height: 30px; line-height: 30px; width: 320px; background: #4479BA;">
<font color="#FFF">
<font color="#FFF">
&nbsp;&nbsp;▸&nbsp;&nbsp;'''Pasteurella Multocida'''
&nbsp;&nbsp;▸&nbsp;&nbsp;'''Pasteurella Multocida'''
Line 270: Line 287:
| style="padding: 0 5px; font-size: 90%; background: #F5F5F5;" align=left | '''''Adults'''''
| style="padding: 0 5px; font-size: 90%; background: #F5F5F5;" align=left | '''''Adults'''''
|-
|-
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | ▸ '''''[[Vancomycin]] 30 mg/kg IV q12h'''''<BR> OR <BR> ▸ '''''[[Linezolid]] 600 mg IV/PO q12h'''''<BR> OR <BR> ▸ '''''[[Clindamycin]] 300-450 mg PO q8h or 600 mg/kg IV q8h'''''<BR> OR <BR> ▸ '''''[[Daptomycin]] 4mg/kg IV q24h'''''<BR> OR <BR> ▸ '''''[[Doxycycline]] 100 mg PO q12h'''''<BR> OR <BR>▸ '''''[[Minocycline]] 100 mg PO q12h'''''<BR> OR <BR> ▸ '''''[[TMP-SMX]] 1 or 2 double-strength tablets ((sulfamethoxazole 800 mg; trimethoprim 160 mg) PO q12h'''''
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | ▸ '''''[[Vancomycin]] 30 mg/kg IV q12h'''''<BR> OR <BR> ▸ '''''[[Linezolid]] 600 mg IV/PO q12h'''''<BR> OR <BR> ▸ '''''[[Clindamycin]] 300-450 mg PO q8h or 600 mg/kg IV q8h'''''<BR> OR <BR> ▸ '''''[[Daptomycin]] 4mg/kg IV q24h'''''<BR> OR <BR> ▸ '''''[[Doxycycline]] 100 mg PO q12h'''''<BR> OR <BR>▸ '''''[[Minocycline]] 100 mg PO q12h'''''<BR> OR <BR> ▸ '''''[[TMP-SMX]] 1 or 2 double-strength tablets (800/160 mg) PO q12h'''''
|-
|-
| style="padding: 0 5px; font-size: 90%; background: #F5F5F5;" align=left | '''''Children age >28 days'''''
| style="padding: 0 5px; font-size: 90%; background: #F5F5F5;" align=left | '''''Children age >28 days'''''
Line 292: Line 309:
| style="padding: 0 5px; font-size: 90%; background: #F5F5F5;" align=left | '''''Children age >28 days'''''
| style="padding: 0 5px; font-size: 90%; background: #F5F5F5;" align=left | '''''Children age >28 days'''''
|-
|-
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | ▸ '''''[[Amoxicillin-clavulanate]] 20 mg/kg PO divided q12h'''''<BR>OR<BR> ▸ '''''[[Ampicillin sulbactam]] 50 mg/kg IV q6h'''''
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | ▸ '''''[[Amoxicillin-clavulanate]] 20 mg/kg PO divided q12h'''''<BR>OR<BR> ▸ '''''[[Ampicillin sulbactam]] 50 mg/kg IV q6h'''''<BR> OR <BR> '''''[[Ertapenem]] 1 g IM/IV q24h'''''
|-
|-
| style="padding: 0 5px; font-size: 90%; background: #F5F5F5;" align=center | '''''Alternative Regimen'''''
| style="padding: 0 5px; font-size: 90%; background: #F5F5F5;" align=center | '''''Alternative Regimen'''''
Line 298: Line 315:
| style="padding: 0 5px; font-size: 90%; background: #F5F5F5;" align=left | '''''Adults'''''
| style="padding: 0 5px; font-size: 90%; background: #F5F5F5;" align=left | '''''Adults'''''
|-
|-
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | ▸ '''''[[Ertapenem]] 1 g IM/IV q24h'''''<BR> OR <BR> ▸ '''''[[Cefoxitin]]  1 g IV q4h or 2 g IV q8h'''''<BR> OR <BR> ▸ '''''[[Meropenem]] 1 g IV q8h'''''<BR> OR <BR> ▸ '''''[[Imipenem cilastatin]] 500 mg IV q6h'''''<BR> OR <BR> ▸ '''''[[Doxycycline]] 100 mg PO/IV q12h PLUS [[Clindamycin]] 450 mg PO or 600 mg IV q8h'''''<BR> OR <BR> ▸ '''''[[TMP-SMX]] 1 double strength tablet (sulfamethoxazole 800 mg; trimethoprim 160 mg) PO q12h or 8-20 mg/kg IV divided q6-12h PLUS [[Clindamycin]] 450 mg PO or 600 mg IV q8h'''''<BR> OR <BR> ▸ '''''[[Moxifloxacin]] 400 mg PO/IV q24h PLUS [[Clindamycin]] 450 mg PO or 600 mg IV q8h'''''
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | ▸ '''''[[Cefoxitin]]  1 g IV q4h or 2 g IV q8h'''''<BR> OR <BR> ▸
'''''[[Meropenem]] 1 g IV q8h'''''<BR> OR <BR> ▸ '''''[[Imipenem cilastatin]] 500 mg IV q6h'''''
|-
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | OR
|-
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | ▸ '''''[[Doxycycline]] 100 mg PO/IV q12h''''' <BR> PLUS <BR> ▸  '''''[[Clindamycin]] 450 mg PO or 600 mg IV q8h'''''
|-
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | OR
|-
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | ▸ '''''[[TMP-SMX]] 1 double strength tablet (800/160 mg) PO q12h or 8-20 mg/kg IV divided q6-12h''''' <BR> PLUS <BR> ▸ '''''[[Clindamycin]] 450 mg PO or 600 mg IV q8h'''''
|-
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | OR
|-
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left |▸ '''''[[Moxifloxacin]] 400 mg PO/IV q24h''''' <BR> PLUS <BR> ▸ '''''[[Clindamycin]] 450 mg PO or 600 mg IV q8h'''''
|-
|-
| style="padding: 0 5px; font-size: 90%; background: #F5F5F5;" align=left | '''''Children age >28 days'''''
| style="padding: 0 5px; font-size: 90%; background: #F5F5F5;" align=left | '''''Children age >28 days'''''
Line 308: Line 338:
|}
|}


===Chronic Lymphangitis===
===Chronic Granulomatous Lymphangitis===


====Pathogen Based Therapy====
====Pathogen Based Therapy====


<SMALL><font color="#FF4C4C">'''▸ Click on the following categories to expand treatment regimens.'''</font><ref name="pmid17968818">{{cite journal| author=Kauffman CA, Bustamante B, Chapman SW, Pappas PG, Infectious Diseases Society of America| title=Clinical practice guidelines for the management of sporotrichosis: 2007 update by the Infectious Diseases Society of America. | journal=Clin Infect Dis | year= 2007 | volume= 45 | issue= 10 | pages= 1255-65 | pmid=17968818 | doi=10.1086/522765 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=17968818  }} </ref><ref name="pmid17277290">{{cite journal| author=Griffith DE, Aksamit T, Brown-Elliott BA, Catanzaro A, Daley C, Gordin F et al.| title=An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases. | journal=Am J Respir Crit Care Med | year= 2007 | volume= 175 | issue= 4 | pages= 367-416 | pmid=17277290 | doi=10.1164/rccm.200604-571ST | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=17277290  }} </ref><ref name="cdc.gov">{{Cite web  | last =  | first =  | title = Parasites - Lymphatic Filariasis | url = http://www.cdc.gov/parasites/lymphaticfilariasis/treatment.html | publisher =  | date =  | accessdate = }}</ref></SMALL>
<SMALL><font color="#FF4C4C">'''▸ Click on the following categories to expand treatment regimens.'''</font></SMALL>


{|
{|
| valign=top |
| valign=top |
<div style="border-radius: 5px 5px 0 0; border: solid 1px #20538D; border-bottom: 0px; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5); box-shadow: inset 0 1px 1px rgba(255, 255, 255, 0.5), 0 1px 1px rgba(0, 0, 0, 0.5); height: 30px; line-height: 30px; width: 310px; background: #A1BCDD; text-align: center;">
<div style="border-radius: 5px 5px 0 0; border: solid 1px #20538D; border-bottom: 0px; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5); box-shadow: inset 0 1px 1px rgba(255, 255, 255, 0.5), 0 1px 1px rgba(0, 0, 0, 0.5); height: 30px; line-height: 30px; width: 320px; background: #A1BCDD; text-align: center;">
<font color="#FFF">
<font color="#FFF">
'''Bacteria'''
'''Bacteria'''
Line 322: Line 352:
</div>
</div>


<div class="mw-customtoggle-table09" style="cursor: pointer; border-radius: 0 0 0 0; border: solid 1px #20538D; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5); box-shadow: inset 0 1px 1px rgba(255, 255, 255, 0.5), 0 1px 1px rgba(0, 0, 0, 0.5); height: 30px; line-height: 30px; width: 310px; background: #4479BA;">
<div class="mw-customtoggle-table09" style="cursor: pointer; border-radius: 0 0 0 0; border: solid 1px #20538D; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5); box-shadow: inset 0 1px 1px rgba(255, 255, 255, 0.5), 0 1px 1px rgba(0, 0, 0, 0.5); height: 30px; line-height: 30px; width: 320px; background: #4479BA;">
<font color="#FFF">
<font color="#FFF">
&nbsp;&nbsp;▸&nbsp;&nbsp;'''Mycobacterium Marinum'''
&nbsp;&nbsp;▸&nbsp;&nbsp;'''Mycobacterium Marinum'''
Line 328: Line 358:
</div>
</div>


<div style="border-radius: 5px 5px 0 0; border: solid 1px #20538D; border-bottom: 0px; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5); box-shadow: inset 0 1px 1px rgba(255, 255, 255, 0.5), 0 1px 1px rgba(0, 0, 0, 0.5); height: 30px; line-height: 30px; width: 310px; background: #A1BCDD; text-align: center;">
<div style="border-radius: 0 0 0 0; border: solid 1px #20538D; border-bottom: 0px; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5); box-shadow: inset 0 1px 1px rgba(255, 255, 255, 0.5), 0 1px 1px rgba(0, 0, 0, 0.5); height: 30px; line-height: 30px; width: 320px; background: #A1BCDD; text-align: center;">
<font color="#FFF">
<font color="#FFF">
'''Fungi'''
'''Fungi'''
Line 334: Line 364:
</div>
</div>


<div class="mw-customtoggle-table10" style="cursor: pointer; border-radius: 0 0 0 0; border: solid 1px #20538D; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5); box-shadow: inset 0 1px 1px rgba(255, 255, 255, 0.5), 0 1px 1px rgba(0, 0, 0, 0.5); height: 30px; line-height: 30px; width: 310px; background: #4479BA;">
<div class="mw-customtoggle-table10" style="cursor: pointer; border-radius: 0 0 0 0; border: solid 1px #20538D; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5); box-shadow: inset 0 1px 1px rgba(255, 255, 255, 0.5), 0 1px 1px rgba(0, 0, 0, 0.5); height: 30px; line-height: 30px; width: 320px; background: #4479BA;">
<font color="#FFF">
<font color="#FFF">
&nbsp;&nbsp;▸&nbsp;&nbsp;'''Sporothrix Schenckii'''
&nbsp;&nbsp;▸&nbsp;&nbsp;'''Sporothrix Schenckii'''
Line 340: Line 370:
</div>
</div>


<div style="border-radius: 5px 5px 0 0; border: solid 1px #20538D; border-bottom: 0px; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5); box-shadow: inset 0 1px 1px rgba(255, 255, 255, 0.5), 0 1px 1px rgba(0, 0, 0, 0.5); height: 30px; line-height: 30px; width: 310px; background: #A1BCDD; text-align: center;">
<div style="border-radius: 0 0 0 0; border: solid 1px #20538D; border-bottom: 0px; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5); box-shadow: inset 0 1px 1px rgba(255, 255, 255, 0.5), 0 1px 1px rgba(0, 0, 0, 0.5); height: 30px; line-height: 30px; width: 320px; background: #A1BCDD; text-align: center;">
<font color="#FFF">
<font color="#FFF">
'''Parasites'''
'''Parasites'''
Line 346: Line 376:
</div>
</div>


<div class="mw-customtoggle-table11" style="cursor: pointer; border-radius: 0 0 0 0; border: solid 1px #20538D; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5); box-shadow: inset 0 1px 1px rgba(255, 255, 255, 0.5), 0 1px 1px rgba(0, 0, 0, 0.5); height: 30px; line-height: 30px; width: 310px; background: #4479BA;">
<div class="mw-customtoggle-table11" style="cursor: pointer; border-radius: 0 0 0 0; border: solid 1px #20538D; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5); box-shadow: inset 0 1px 1px rgba(255, 255, 255, 0.5), 0 1px 1px rgba(0, 0, 0, 0.5); height: 30px; line-height: 30px; width: 320px; background: #4479BA;">
<font color="#FFF">
<font color="#FFF">
&nbsp;&nbsp;▸&nbsp;&nbsp;'''Brugia Malayi'''
&nbsp;&nbsp;▸&nbsp;&nbsp;'''Brugia Malayi'''
Line 352: Line 382:
</div>
</div>


<div class="mw-customtoggle-table12" style="cursor: pointer; border-radius: 0 0 5px 5px; border: solid 1px #20538D; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5); box-shadow: inset 0 1px 1px rgba(255, 255, 255, 0.5), 0 1px 1px rgba(0, 0, 0, 0.5); height: 30px; line-height: 30px; width: 310px; background: #4479BA;">
<div class="mw-customtoggle-table12" style="cursor: pointer; border-radius: 0 0 5px 5px; border: solid 1px #20538D; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5); box-shadow: inset 0 1px 1px rgba(255, 255, 255, 0.5), 0 1px 1px rgba(0, 0, 0, 0.5); height: 30px; line-height: 30px; width: 320px; background: #4479BA;">
<font color="#FFF">
<font color="#FFF">
&nbsp;&nbsp;▸&nbsp;&nbsp;'''Wuchereria Bancrofti'''
&nbsp;&nbsp;▸&nbsp;&nbsp;'''Wuchereria Bancrofti'''
Line 366: Line 396:
| style="padding: 0 5px; font-size: 90%; background: #F5F5F5;" align=center | '''''Preferred Regimen'''''
| style="padding: 0 5px; font-size: 90%; background: #F5F5F5;" align=center | '''''Preferred Regimen'''''
|-
|-
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | ▸ '''''[[Clarithromycin]] 500 mg PO q12h PLUS [[Ethambutol]] 15 mg/kg PO q24h'''''<BR> OR <BR> ▸ '''''[[Rifampin]] 600 mg PO q24h'''''
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | ▸ '''''[[Clarithromycin]] 500 mg PO q12h'''''
|-
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | PLUS
|-
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | ▸ '''''[[Ethambutol]] 15 mg/kg PO q24h'''''
|-
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | OR ▸ '''''[[Rifampin]] 600 mg PO q24h'''''
|-
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | PLUS
|-
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | ▸ '''''[[Ethambutol]] 15 mg/kg PO q24h'''''
|-
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | <small>''Adapted from
Eur J Clin Microbiol Infect Dis. 2006 Oct;25(10):609-13.''<ref name="pmid17047903">{{cite journal| author=Petrini B| title=Mycobacterium marinum: ubiquitous agent of waterborne granulomatous skin infections. | journal=Eur J Clin Microbiol Infect Dis | year= 2006 | volume= 25 | issue= 10 | pages= 609-13 | pmid=17047903 | doi=10.1007/s10096-006-0201-4 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=17047903  }} </ref> ''Am J Respir Crit Care Med. 2007 Feb 15;175(4):367-416.''<ref name="pmid17277290">{{cite journal| author=Griffith DE, Aksamit T, Brown-Elliott BA, Catanzaro A, Daley C, Gordin F et al.| title=An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases. | journal=Am J Respir Crit Care Med | year= 2007 | volume= 175 | issue= 4 | pages= 367-416 | pmid=17277290 | doi=10.1164/rccm.200604-571ST | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=17277290  }} </ref></small>
|-
|-
|}
|}
Line 378: Line 421:
| style="padding: 0 5px; font-size: 90%; background: #F5F5F5;" align=center | '''''Preferred Regimen'''''
| style="padding: 0 5px; font-size: 90%; background: #F5F5F5;" align=center | '''''Preferred Regimen'''''
|-
|-
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | ▸ '''''[[Itraconazole]] 200 mg PO q12h'''''
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | ▸ '''''[[Itraconazole]] 200 mg PO q24h'''''
|-
|-
| style="padding: 0 5px; font-size: 90%; background: #F5F5F5;" align=center | '''''Alternative Regimen'''''
| style="padding: 0 5px; font-size: 90%; background: #F5F5F5;" align=center | '''''Alternative Regimen†'''''
|-
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | ▸ '''''[[Itraconazole]] 200 mg PO q12h'''''<BR> OR <BR> ▸ '''''[[Terbinafine]] 500 mg PO q12h'''''<BR> OR <BR> ▸ '''''[[Potassium iodide|Saturated solution of potassium iodide]] 5-50 drops q8h'''''<BR> OR <BR> ▸ '''''[[Fluconazole]]¶ 400-800 mg/day PO'''''
|-
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | <SMALL><sup>†</sup> If there is no improvement after preferred treatment <br> <sup>¶</sup> Only administer if patient can't tolerate other antifungal agents</SMALL>
|-
|-
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | ▸ '''''[[Terbinafine]] 500 mg PO q12h'''''<BR> OR <BR> ▸ '''''[[Potassium iodide|Saturated solution of potassium iodide]] 5-50 drops q8h'''''<BR> OR <BR> ▸ '''''[[Fluconazole]] 400-800 mg/day PO'''''
| style="padding: 0 5px; font-size: 90%; background: #F5F5F5;" align=center | <small> ''Adapted from Clin Infect Dis. 2007 Nov 15;45(10):1255-65. Epub 2007 Oct 8'' <ref name="pmid17968818">{{cite journal| author=Kauffman CA, Bustamante B, Chapman SW, Pappas PG, Infectious Diseases Society of America| title=Clinical practice guidelines for the management of sporotrichosis: 2007 update by the Infectious Diseases Society of America. | journal=Clin Infect Dis | year= 2007 | volume= 45 | issue= 10 | pages= 1255-65 | pmid=17968818 | doi=10.1086/522765 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=17968818  }} </ref></small>
|-
|-
|}
|}
Line 396: Line 443:


| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | ▸ '''''[[Diethylcarbamazine]] 6 mg/kg/day PO'''''
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | ▸ '''''[[Diethylcarbamazine]] 6 mg/kg/day PO'''''
|-
| style="padding: 0 5px; font-size: 90%; background: #F5F5F5;" align=center | <small> ''Adapted from Parasites - Lymphatic Filariasis CDC page.'' <ref name="cdc.gov">{{Cite web  | last =  | first =  | title = Parasites - Lymphatic Filariasis | url = http://www.cdc.gov/parasites/lymphaticfilariasis/treatment.html | publisher =  | date =  | accessdate = }}</ref></small>
|-
|-
|}
|}
Line 409: Line 458:
|-
|-
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | ▸ '''''[[Diethylcarbamazine]] 6 mg/kg/day PO'''''
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | ▸ '''''[[Diethylcarbamazine]] 6 mg/kg/day PO'''''
|-
| style="padding: 0 5px; font-size: 90%; background: #F5F5F5;" align=center | <small> ''Adapted from Parasites - Lymphatic Filariasis CDC page.'' <ref name="cdc.gov">{{Cite web  | last =  | first =  | title = Parasites - Lymphatic Filariasis | url = http://www.cdc.gov/parasites/lymphaticfilariasis/treatment.html | publisher =  | date =  | accessdate = }}</ref></small>
|-
|-
|}
|}
|}
|}
|}
|}
===Lymphantic Filarisis===
*Lymphatic [[filariasis]] can be treated with a one-day or a 12-day [[diethylcarbamazine]] regimen.  The one-day regimen is as effective as the 12-day regimen.<ref name="cdc.gov">{{Cite web  | last =  | first =  | title = Parasites - Lymphatic Filariasis | url = http://www.cdc.gov/parasites/lymphaticfilariasis/treatment.html | publisher =  | date =  | accessdate = }}</ref>
== Lymphangitis due to non-infectious etiology ==
Medical therapy for lymphangitis due to non-infectious etiology include:
===Lymphangitic carcinomatosis===
*Currently, no effective strategies available in treating lymphangitis carcinomatosa <ref name="pmid22693377">{{cite journal| author=Raja A, Seshadri RA, Sundersingh S| title=Lymphangitis carcinomatosa: report of a case and review of literature. | journal=Indian J Surg Oncol | year= 2010 | volume= 1 | issue= 3 | pages= 274-6 | pmid=22693377 | doi=10.1007/s13193-011-0047-9 | pmc=3244248 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=22693377  }} </ref>
*Steroid administration could produce symptomatic improvement mainly by alleviating breathlessness.<ref name="pmid8930034">{{cite journal| author=Bruce DM, Heys SD, Eremin O| title=Lymphangitis carcinomatosa: a literature review. | journal=J R Coll Surg Edinb | year= 1996 | volume= 41 | issue= 1 | pages= 7-13 | pmid=8930034 | doi= | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=8930034  }} </ref>
*Poor prognosis<ref name="pmid8930034">{{cite journal| author=Bruce DM, Heys SD, Eremin O| title=Lymphangitis carcinomatosa: a literature review. | journal=J R Coll Surg Edinb | year= 1996 | volume= 41 | issue= 1 | pages= 7-13 | pmid=8930034 | doi= | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=8930034  }} </ref>
=== Sclerosis Lymphangitis ===
* Sclerosis lymphangitis is a self-limiting disease, resolving spontaneously within several weeks, if restrained from vigorous sexual activity.<ref name="pmid26228831" /><ref name="pmid25592644" />
* No treatment is required, NSAID's have been recommended but without proven benefit.


==References==
==References==
{{reflist|2}}
{{reflist|2}}
{{WH}}
{{WH}}
{{WS}}
{{WS}}


[[Category:Inflammations]]
[[Category:Inflammations]]
[[Category:Disease]]
[[Category:Emergency mdicine]]
[[Category:Up-To-Date]]
[[Category:Infectious disease]]
[[Category:Infectious disease]]
[[Category:Disease]]
[[Category:Vascular medicine]]
[[Category:Signs and symptoms]]

Latest revision as of 22:36, 29 July 2020

Lymphangitis Microchapters

Home

Overview

Historical Perspective

Classification

Causes

Pathophysiology

Differentiating Lymphangitis from other Diseases

Epidemiology and Demographics

Risk Factors

Natural History, Complications and Prognosis

Diagnosis

History and Symptoms

Physical Examination

Laboratory Findings

X Ray

CT

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Prevention

Case Studies

Case #1

Lymphangitis medical therapy On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Lymphangitis medical therapy

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Lymphangitis medical therapy

CDC on Lymphangitis medical therapy

Lymphangitis medical therapy in the news

Blogs on Lymphangitis medical therapy

Directions to Hospitals Treating Lymphangitis

Risk calculators and risk factors for Lymphangitis medical therapy

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Vendhan Ramanujam M.B.B.S [2],Faizan Sheraz, M.D. [3]Vishal Devarkonda, M.B.B.S[4]

Overview

Lymphangitis being a manifestation of wide concurrently occurring spectrum of manifestations or pathologies.The medical therapy varies from etiology to etiology. The mainstay of therapy for lymphangitis of infectious origin is antimicrobial therapy. Supportive therapy includes analgesics, anti-inflammatory agents, and warm compresses. Specific anitmicrobial treatment for individual infections are discussed in detail separately.

Medical Therapy

The mainstay of therapy for lymphangitis of infectious origin is antimicrobial therapy. Supportive therapy includes analgesics, anti-inflammatory agents, and warm compresses.

[1]

Lymphangitis of infectious etiology

Common preferred and accepted therapy for lymphangitis of infectious origin include: Dicloxacillin or Cephalexin

  • 2. Patient with lymphangitis and if Community-Associated Methicillin-Resistant Staphylococcus Aureus (CA-MRSA) suspected:
  • 3.Patient with lymphangitis allergic to penicillin:

Empiric Therapy Adapted from Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases.[2]Adapted from Clin Infect Dis. 2005 Nov 15;41(10):1373-406.[3] J Emerg Med. 2013 Jun;44(6):e397-412.[4]Clin Infect Dis. 2011 Feb 1;52(3):e18-55.[5]

▸ Click on the following categories to expand treatment regimens.

Mild - Moderate Acute Lymphangitis

  ▸  Adults

  ▸  Children age >28 days

Severe Acute Lymphangitis

  ▸  Adults

  ▸  Children age >28 days

Mild - Moderate Acute Lymphangitis - Adults
Preferred Regimen
Penicillin V 500 mg PO q6h
Alternative Regimen
For Suspected Methicillin-Sensitive Staphylococcus Aureus (MSSA)
Dicloxacillin 500 mg PO q6h
OR
Cephalexin 500 mg PO q6h
For Suspected Methicillin-Resistant Staphylococcus Aureus (MRSA)
Clindamycin 300-450 mg PO q8h
OR
TMP-SMX 1 or 2 double-strength tablets (160/800 mg) PO q12h
OR
Doxycycline 100 mg PO q12h
OR
Minocycline 100 mg PO q12h
OR
Linezolid 600 mg PO q12h
For Suspected Beta-Hemolytic Streptococci and Methicillin-Resistant Staphylococcus Aureus (MRSA)
Clindamycin 300-450 mg PO q8h
OR
Amoxicillin 500 mg PO q8h
PLUS
TMP-SMX 1 or 2 double-strength tablets (sulfamethoxazole 800 mg; trimethoprim 160 mg) PO q12h
OR
Doxycycline 100 mg PO q12h
OR
Minocycline 100 mg PO q12h
OR
Linezolid 600 mg PO q12h
For Animal Bites
Amoxicillin-clavulanate 875 mg PO q12h
Mild - Moderate Acute Lymphangitis - Children
Preferred Regimen
Penicillin V < 12 years-old 25-50 mg/kg/day PO divided q6-8h (maximum 3 g/day), > 12 years-old 250-500 mg PO q6-8h
Alternative Regimen
For Suspected Methicillin-Sensitive Staphylococcus Aureus (MSSA)
Dicloxacillin 25 mg/kg PO divided q6h
OR
Cephalexin 25 mg/kg PO divided q6h
For Suspected Methicillin-Resistant Staphylococcus Aureus (MRSA)
Clindamycin 10-13 mg/kg PO q6-8h
OR
TMP-SMX 8–12 mg/kg (based on trimethoprim component) PO q12h
OR
Doxycycline¶ ≤45 kg: 2 mg/kg PO q12h; >45 kg: 100 mg PO q12h
OR
Minocycline 2 mg/kg PO q12h ¶
OR
Linezolid 10 mg/kg PO q8h
Not recommended for children < 8 years of age
For Suspected Beta-Hemolytic Streptococci and Methicillin-Resistant Staphylococcus Aureus (MRSA)
Clindamycin 10-13 mg/kg IV q6-8h
OR
Amoxicillin 500 mg PO q8h
PLUS
TMP-SMX 8–12 mg/kg (based on trimethoprim component) PO q12h
OR
Doxycycline¶ ≤45 kg: 2 mg/kg PO q12h; >45 kg: 100 mg PO q12h
OR
Minocycline¶ 2 mg/kg PO q12h
OR
Linezolid 10 mg/kg PO q8h
Not recommended for children < 8 years of age
For Animal Bites
Amoxicillin-clavulanate 20 mg/kg PO divided q12h
Severe Acute Lymphangitis - Adults
Preferred Regimen
Penicillin G 2-4 MU IV q4-6h
Alternative Regimen
For Suspected Methicillin-Sensitive Staphylococcus Aureus (MSSA)
Nafcillin 1-2 g IV q4h
OR
Oxacillin 1-2 g IV q4h
OR
Cefazolin 1 g IV q8h
OR
Clindamycin 300-450 mg PO q8h
For Suspected Methicillin-Resistant Staphylococcus Aureus (MRSA)
Vancomycin 15-20 mg/kg IV q8-12h
OR
Linezolid 600 mg IV/PO q12h
OR
Daptomycin 4mg/kg IV q24h
OR
Clindamycin 600 mg IV/PO q8h
OR
Telavancin 10 mg/kg IV q12h
For Suspected Beta-Hemolytic Streptococci and Methicillin-Resistant Staphylococcus Aureus (MRSA)
Clindamycin 600 mg IV/PO q8h
OR
Linezolid 600 mg IV/PO q12h
For Animal Bites
Ampicillin sulbactam 3 g IV q6h
Severe Acute Lymphangitis - Children
Preferred Regimen
Penicillin G 2-4 MU IV q4-6h
Alternative Regimen
For Suspected Methicillin-Sensitive Staphylococcus Aureus (MSSA)
Nafcillin 100–150 mg/kg IV q6h
OR
Oxacillin 100–150 mg/kg IV q6h
OR
Cefazolin 50 mg/kg IV q8h
OR
Clindamycin 10-13 mg/kg IV q6-8h
OR
Erythromycin 10 mg/kg PO q6h
For Suspected Methicillin-Resistant Staphylococcus Aureus (MRSA)
Vancomycin 15 mg/kg IV q6h
OR
Linezolid 10 mg/kg IV/PO q8h
OR
Daptomycin 5-9 mg/kg IV q24h
OR
Clindamycin 10-13 mg/kg IV/PO q6-8h
For Suspected Beta-Hemolytic Streptococci and Methicillin-Resistant Staphylococcus Aureus (MRSA)
Clindamycin 10-13 mg/kg IV/PO q6-8h
OR
Linezolid 10 mg/kg IV/PO q8h
For Animal Bites
Ampicillin sulbactam 50 mg/kg IV q6h

Pathogen Based Therapy Adapted from Clin Infect Dis. 2005 Nov 15;41(10):1373-406.[3] J Emerg Med. 2013 Jun;44(6):e397-412.[4]Clin Infect Dis. 2011 Feb 1;52(3):e18-55.[5]

▸ Click on the following categories to expand treatment regimens.

Bacteria

  ▸  Streptococcus Pyogenes

  ▸  Methicillin Sensitive Staphylococcus Aureus

  ▸  Methicillin Resistant Staphylococcus Aureus

  ▸  Pasteurella Multocida

Streptococcus Pyogenes
Preferred Regimen
Penicillin V 500 mg PO q6h
OR
Penicillin G 2-4 MU IV q4-6h
Alternative Regimen
For Life-Threatening Penicillin Allergies
Adults
Clindamycin 300-450 mg PO q8h
OR
Vancomycin 15-20 mg/kg IV q8-12h
Children age >28 days
Clindamycin 10-13 mg/kg IV q6-8h
OR
Vancomycin 15 mg/kg IV q6h
Methicillin-Sensitive Staphylococcus Aureus (MSSA)
Preferred Regimen
Adults
Nafcillin 1-2 g IV q4h
OR
Oxacillin 1-2 g IV q4h
OR
Cefazolin 1 g IV q8h
OR
Clindamycin 300-450 mg PO q8h or 600 mg/kg IV q8h
OR
Erythromycin 500 mg PO q6h
OR
Dicloxacillin 500 mg PO q6h
OR
Cephalexin 500 mg PO q6h
OR
Doxycycline 100 mg PO q12h
OR
Minocycline 100 mg PO q12h
OR
TMP-SMX 1 or 2 double-strength tablets ((sulfamethoxazole 800 mg; trimethoprim 160 mg) PO q12h
Children age >28 days
Nafcillin 100–150 mg/kg IV q6h
OR
Oxacillin 100–150 mg/kg IV q6h
OR
Cefazolin 50 mg/kg IV q8h
OR
Clindamycin 10–20 mg/kg PO q8h or 25–40 mg/kg IV q8h
OR
Erythromycin 10 mg/kg PO q6h
OR
Dicloxacillin 25 mg/kg PO q6h
OR
Cephalexin 25 mg/kg PO q6h
OR
TMP-SMX 8–12 mg/kg (based on trimethoprim component) IV q6h/PO q12h
Methicillin-Resistant Staphylococcus Aureus (MRSA)
Preferred Regimen
Adults
Vancomycin 30 mg/kg IV q12h
OR
Linezolid 600 mg IV/PO q12h
OR
Clindamycin 300-450 mg PO q8h or 600 mg/kg IV q8h
OR
Daptomycin 4mg/kg IV q24h
OR
Doxycycline 100 mg PO q12h
OR
Minocycline 100 mg PO q12h
OR
TMP-SMX 1 or 2 double-strength tablets (800/160 mg) PO q12h
Children age >28 days
Vancomycin 40 mg/kg IV q6h
OR
Linezolid 10 mg/kg IV/PO q12h
OR
Clindamycin 10–20 mg/kg PO q8h or 25–40 mg/kg IV q8h
OR
TMP-SMX 8–12 mg/kg (based on trimethoprim component) IV q6h/PO q12h
Pasteurella Multocida
Preferred Regimen
Adults
Amoxicillin-clavulanate 875 mg PO q12h
OR
Ampicillin sulbactam 3 g IV q6h
Children age >28 days
Amoxicillin-clavulanate 20 mg/kg PO divided q12h
OR
Ampicillin sulbactam 50 mg/kg IV q6h
OR
Ertapenem 1 g IM/IV q24h
Alternative Regimen
Adults
Cefoxitin 1 g IV q4h or 2 g IV q8h
OR

Meropenem 1 g IV q8h
OR
Imipenem cilastatin 500 mg IV q6h

OR
Doxycycline 100 mg PO/IV q12h
PLUS
Clindamycin 450 mg PO or 600 mg IV q8h
OR
TMP-SMX 1 double strength tablet (800/160 mg) PO q12h or 8-20 mg/kg IV divided q6-12h
PLUS
Clindamycin 450 mg PO or 600 mg IV q8h
OR
Moxifloxacin 400 mg PO/IV q24h
PLUS
Clindamycin 450 mg PO or 600 mg IV q8h
Children age >28 days
Ertapenem 15 mg/kg IM/IV q12h
OR
Cefoxitin 160 mg/kg IV divided q4-6h
OR
Meropenem 20 mg/kg IV q8h
OR
Imipenem cilastatin 25 mg/kg IV q6h
OR
TMP-SMX 4-5 mg/kg (trimethoprim component) PO/IV q12h
PLUS
Clindamycin 10 mg/kg PO/IV q8h

Chronic Granulomatous Lymphangitis

Pathogen Based Therapy

▸ Click on the following categories to expand treatment regimens.

Bacteria

  ▸  Mycobacterium Marinum

Fungi

  ▸  Sporothrix Schenckii

Parasites

  ▸  Brugia Malayi

  ▸  Wuchereria Bancrofti

Mycobacterium Marinum
Preferred Regimen
Clarithromycin 500 mg PO q12h
PLUS
Ethambutol 15 mg/kg PO q24h
OR ▸ Rifampin 600 mg PO q24h
PLUS
Ethambutol 15 mg/kg PO q24h
Adapted from

Eur J Clin Microbiol Infect Dis. 2006 Oct;25(10):609-13.[6] Am J Respir Crit Care Med. 2007 Feb 15;175(4):367-416.[7]

Sporothrix Schenckii
Preferred Regimen
Itraconazole 200 mg PO q24h
Alternative Regimen†
Itraconazole 200 mg PO q12h
OR
Terbinafine 500 mg PO q12h
OR
Saturated solution of potassium iodide 5-50 drops q8h
OR
Fluconazole¶ 400-800 mg/day PO
If there is no improvement after preferred treatment
Only administer if patient can't tolerate other antifungal agents
Adapted from Clin Infect Dis. 2007 Nov 15;45(10):1255-65. Epub 2007 Oct 8 [8]
Brugia Malayi
Preferred Regimen
Diethylcarbamazine 6 mg/kg/day PO
Adapted from Parasites - Lymphatic Filariasis CDC page. [9]
Wuchereria Bancrofti
Preferred Regimen
Diethylcarbamazine 6 mg/kg/day PO
Adapted from Parasites - Lymphatic Filariasis CDC page. [9]

Lymphantic Filarisis

Lymphangitis due to non-infectious etiology

Medical therapy for lymphangitis due to non-infectious etiology include:

Lymphangitic carcinomatosis

  • Currently, no effective strategies available in treating lymphangitis carcinomatosa [10]
  • Steroid administration could produce symptomatic improvement mainly by alleviating breathlessness.[11]
  • Poor prognosis[11]

Sclerosis Lymphangitis

  • Sclerosis lymphangitis is a self-limiting disease, resolving spontaneously within several weeks, if restrained from vigorous sexual activity.[12][13]
  • No treatment is required, NSAID's have been recommended but without proven benefit.

References

  1. lymphanitis Mandell, GERALD L. "Mandell, Douglas, and Bennett's." Principles and practice of infectious diseases 7 (1995) Accessed on October 12,2016
  2. Mandell, Gerald L.; Bennett, John E. (John Eugene); Dolin, Raphael. (2010). Mandell, Douglas, and Bennett's principles and practice of infectious disease. Philadelphia, PA: Churchill Livingstone/Elsevier.
  3. 3.0 3.1 Stevens DL, Bisno AL, Chambers HF, Everett ED, Dellinger P, Goldstein EJ; et al. (2005). "Practice guidelines for the diagnosis and management of skin and soft-tissue infections". Clin Infect Dis. 41 (10): 1373–406. doi:10.1086/497143. PMID 16231249.
  4. 4.0 4.1 Moran GJ, Abrahamian FM, Lovecchio F, Talan DA (2013). "Acute bacterial skin infections: developments since the 2005 Infectious Diseases Society of America (IDSA) guidelines". J Emerg Med. 44 (6): e397–412. doi:10.1016/j.jemermed.2012.11.050. PMID 23466022.
  5. 5.0 5.1 Liu C, Bayer A, Cosgrove SE, Daum RS, Fridkin SK, Gorwitz RJ; et al. (2011). "Clinical practice guidelines by the infectious diseases society of america for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children". Clin Infect Dis. 52 (3): e18–55. doi:10.1093/cid/ciq146. PMID 21208910.
  6. Petrini B (2006). "Mycobacterium marinum: ubiquitous agent of waterborne granulomatous skin infections". Eur J Clin Microbiol Infect Dis. 25 (10): 609–13. doi:10.1007/s10096-006-0201-4. PMID 17047903.
  7. Griffith DE, Aksamit T, Brown-Elliott BA, Catanzaro A, Daley C, Gordin F; et al. (2007). "An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases". Am J Respir Crit Care Med. 175 (4): 367–416. doi:10.1164/rccm.200604-571ST. PMID 17277290.
  8. Kauffman CA, Bustamante B, Chapman SW, Pappas PG, Infectious Diseases Society of America (2007). "Clinical practice guidelines for the management of sporotrichosis: 2007 update by the Infectious Diseases Society of America". Clin Infect Dis. 45 (10): 1255–65. doi:10.1086/522765. PMID 17968818.
  9. 9.0 9.1 9.2 "Parasites - Lymphatic Filariasis".
  10. Raja A, Seshadri RA, Sundersingh S (2010). "Lymphangitis carcinomatosa: report of a case and review of literature". Indian J Surg Oncol. 1 (3): 274–6. doi:10.1007/s13193-011-0047-9. PMC 3244248. PMID 22693377.
  11. 11.0 11.1 Bruce DM, Heys SD, Eremin O (1996). "Lymphangitis carcinomatosa: a literature review". J R Coll Surg Edinb. 41 (1): 7–13. PMID 8930034.

Template:WH Template:WS